These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28671001)

  • 1. Between pharmaceutical patents and European patients: is a compromise still possible?
    Garattini L; Padula A
    Expert Opin Ther Pat; 2017 Oct; 27(10):1073-1076. PubMed ID: 28671001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [What future for the pharmaceutical patenting in europe: reforming or getting rid of it?].
    Badinella Martini M; Nobili A; Garattini L
    Recenti Prog Med; 2022 Mar; 113(3):157-160. PubMed ID: 35315444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
    Xu Z; Chen W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
    Prugnaud JL
    Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the risks of second medical use and dosing regimens in pharmaceutical patenting?
    Kanz C; Gerhardt F
    Pharm Pat Anal; 2014 Sep; 3(5):481-4. PubMed ID: 25374316
    [No Abstract]   [Full Text] [Related]  

  • 8. Patent protection in Europe of pharmaceuticals found to have a further medical indication.
    Cockbain J
    Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708
    [No Abstract]   [Full Text] [Related]  

  • 9. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

  • 10. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 12. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.
    Kesselheim AS
    AAPS J; 2007 Aug; 9(3):E306-11. PubMed ID: 17915832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience.
    Ortiz-Prado E; Cevallos-Sierra G; Teran E; Vasconez E; Borrero-Maldonado D; Ponce Zea J; Simbaña-Rivera K; Gómez-Barreno L
    Expert Opin Ther Pat; 2019 Aug; 29(8):653-662. PubMed ID: 31298053
    [No Abstract]   [Full Text] [Related]  

  • 15. IP issues facing researchers by Gino D'Oca.
    Almarsson O; Angiolini M; Baell J; Giardina G; Ingham A; Hughes A; Pevarello P; Sindelar R
    Pharm Pat Anal; 2012 May; 1(2):129-35. PubMed ID: 24236778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better protection for patentees: preliminary injunctions in the EU for pharmaceutical patent matters.
    von Falck A; Gundt M
    Pharm Pat Anal; 2013 May; 2(3):291-3. PubMed ID: 24237054
    [No Abstract]   [Full Text] [Related]  

  • 17. Patenting pharmaceuticals in China.
    Han W; Luo J
    Pharm Pat Anal; 2016 Jul; 5(4):249-59. PubMed ID: 27338759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
    Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract]   [Full Text] [Related]  

  • 19. Intellectual property. Fixing the legal framework for pharmaceutical research.
    Knowles SM
    Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
    [No Abstract]   [Full Text] [Related]  

  • 20. Enforcing pharmaceutical and biotech patent rights in China.
    Zhang YP; Deng MM
    Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.